ketamine has been researched along with Peripheral Nerve Diseases in 25 studies
Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.
ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sixteen patients with neuropathic pain of various origins were randomized into two treatment groups: (S)-ketamine 0." | 9.14 | Effects of low-dose intranasal (S)-ketamine in patients with neuropathic pain. ( Azad, SC; Beyer, A; Huge, V; Lauchart, M; Magerl, W; Schelling, G; Thieme, D, 2010) |
| "Ketamine significantly reduced ongoing pain and evoked pain to brush and pinprick, whereas lidocaine only reduced evoked pain to repetitive pinprick stimuli." | 9.12 | Differential effect of ketamine and lidocaine on spontaneous and mechanical evoked pain in patients with nerve injury pain. ( Bach, FW; Gottrup, H; Jensen, TS; Juhl, G, 2006) |
| "The analgesic effect of the N-methyl-D-aspartate (NMDA) receptor blocker ketamine in 17 patients (13 females and four males, age 32-88 years) who had suffered neuropathic orofacial pain for time periods ranging from 6 months to 28 years was examined." | 9.09 | Interindividual differences in the analgesic response to ketamine in chronic orofacial pain. ( Rabben, T; Øye, I, 2001) |
| "Ten patients (4 female, 6 male) aged 34-67 years suffering from peripheral neuropathic pain participated in a double-blind placebo-controlled study where ketamine or magnesium chloride were administered by a 10 min bolus infusion (ketamine: 0." | 9.08 | NMDA receptor blockade in chronic neuropathic pain: a comparison of ketamine and magnesium chloride. ( Arendt-Nielsen, L; Felsby, S; Jensen, TS; Nielsen, J, 1996) |
| "The therapeutic effects of dextrorphan and ketamine, two non-competitive N-methyl-D-aspartate (NMDA) receptor antagonists, on neuropathic pain-related behaviors were examined in rats with peripheral mononeuropathy induced by loose ligation of the common sciatic nerve (chronic constrictive injury, CCI)." | 7.68 | Intrathecal treatment with dextrorphan or ketamine potently reduces pain-related behaviors in a rat model of peripheral mononeuropathy. ( Frenk, H; Hayes, RL; Lu, J; Mao, J; Mayer, DJ; Price, DD, 1993) |
| "Cold allodynia and hyperalgesia are frequent clinical findings in patients with neuropathic pain." | 6.71 | Cold allodynia and hyperalgesia in neuropathic pain: the effect of N-methyl-D-aspartate (NMDA) receptor antagonist ketamine--a double-blind, cross-over comparison with alfentanil and placebo. ( Jørum, E; Stubhaug, A; Warncke, T, 2003) |
| "It had less effect on tactile allodynia (CCI)." | 5.35 | Effects of norketamine enantiomers in rodent models of persistent pain. ( Crooks, PA; Hojomat, M; Holtman, JR; Johnson-Hardy, JK; Kleven, M; Wala, EP, 2008) |
| "Sixteen patients with neuropathic pain of various origins were randomized into two treatment groups: (S)-ketamine 0." | 5.14 | Effects of low-dose intranasal (S)-ketamine in patients with neuropathic pain. ( Azad, SC; Beyer, A; Huge, V; Lauchart, M; Magerl, W; Schelling, G; Thieme, D, 2010) |
| "Ketamine significantly reduced ongoing pain and evoked pain to brush and pinprick, whereas lidocaine only reduced evoked pain to repetitive pinprick stimuli." | 5.12 | Differential effect of ketamine and lidocaine on spontaneous and mechanical evoked pain in patients with nerve injury pain. ( Bach, FW; Gottrup, H; Jensen, TS; Juhl, G, 2006) |
| "The analgesic effect of the N-methyl-D-aspartate (NMDA) receptor blocker ketamine in 17 patients (13 females and four males, age 32-88 years) who had suffered neuropathic orofacial pain for time periods ranging from 6 months to 28 years was examined." | 5.09 | Interindividual differences in the analgesic response to ketamine in chronic orofacial pain. ( Rabben, T; Øye, I, 2001) |
| "Ten patients (4 female, 6 male) aged 34-67 years suffering from peripheral neuropathic pain participated in a double-blind placebo-controlled study where ketamine or magnesium chloride were administered by a 10 min bolus infusion (ketamine: 0." | 5.08 | NMDA receptor blockade in chronic neuropathic pain: a comparison of ketamine and magnesium chloride. ( Arendt-Nielsen, L; Felsby, S; Jensen, TS; Nielsen, J, 1996) |
| " In the present study, morphine (a low dose) was combined with S(+)- and R(-)-norketamine (sub-antinociceptive doses) and characterized utilizing rodent models of pain including: thermal nociception (the tail-flick test), peripheral neuropathy (chronic constriction nerve injury) and tonic inflammatory pain (the formalin test)." | 3.74 | Interaction between morphine and norketamine enantiomers in rodent models of nociception. ( Crooks, PA; Holtman, JR; Johnson-Hardy, J; Wala, EP, 2008) |
| "The therapeutic effects of dextrorphan and ketamine, two non-competitive N-methyl-D-aspartate (NMDA) receptor antagonists, on neuropathic pain-related behaviors were examined in rats with peripheral mononeuropathy induced by loose ligation of the common sciatic nerve (chronic constrictive injury, CCI)." | 3.68 | Intrathecal treatment with dextrorphan or ketamine potently reduces pain-related behaviors in a rat model of peripheral mononeuropathy. ( Frenk, H; Hayes, RL; Lu, J; Mao, J; Mayer, DJ; Price, DD, 1993) |
| "Cold allodynia and hyperalgesia are frequent clinical findings in patients with neuropathic pain." | 2.71 | Cold allodynia and hyperalgesia in neuropathic pain: the effect of N-methyl-D-aspartate (NMDA) receptor antagonist ketamine--a double-blind, cross-over comparison with alfentanil and placebo. ( Jørum, E; Stubhaug, A; Warncke, T, 2003) |
| "It had less effect on tactile allodynia (CCI)." | 1.35 | Effects of norketamine enantiomers in rodent models of persistent pain. ( Crooks, PA; Hojomat, M; Holtman, JR; Johnson-Hardy, JK; Kleven, M; Wala, EP, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (16.00) | 18.2507 |
| 2000's | 14 (56.00) | 29.6817 |
| 2010's | 7 (28.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hardy, J | 1 |
| Quinn, S | 1 |
| Fazekas, B | 1 |
| Agar, M | 1 |
| Currow, D | 1 |
| Gewandter, JS | 1 |
| Mohile, SG | 1 |
| Heckler, CE | 1 |
| Ryan, JL | 1 |
| Kirshner, JJ | 1 |
| Flynn, PJ | 1 |
| Hopkins, JO | 1 |
| Morrow, GR | 1 |
| Hershman, DL | 1 |
| Lacchetti, C | 1 |
| Dworkin, RH | 1 |
| Lavoie Smith, EM | 1 |
| Bleeker, J | 1 |
| Cavaletti, G | 1 |
| Chauhan, C | 1 |
| Gavin, P | 1 |
| Lavino, A | 1 |
| Lustberg, MB | 1 |
| Paice, J | 1 |
| Schneider, B | 1 |
| Smith, ML | 1 |
| Smith, T | 1 |
| Terstriep, S | 1 |
| Wagner-Johnston, N | 1 |
| Bak, K | 1 |
| Loprinzi, CL | 2 |
| Wolf, S | 1 |
| Barton, D | 1 |
| Kottschade, L | 1 |
| Grothey, A | 1 |
| Loprinzi, C | 1 |
| Holtman, JR | 2 |
| Crooks, PA | 2 |
| Johnson-Hardy, J | 1 |
| Wala, EP | 2 |
| Johnson-Hardy, JK | 1 |
| Hojomat, M | 1 |
| Kleven, M | 1 |
| Prommer, EE | 1 |
| Huge, V | 1 |
| Lauchart, M | 1 |
| Magerl, W | 1 |
| Schelling, G | 1 |
| Beyer, A | 1 |
| Thieme, D | 1 |
| Azad, SC | 1 |
| Boettger, MK | 1 |
| Weber, K | 1 |
| Gajda, M | 1 |
| Bräuer, R | 1 |
| Schaible, HG | 1 |
| Vranken, JH | 1 |
| Barton, DL | 1 |
| Wos, EJ | 1 |
| Qin, R | 1 |
| Mattar, BI | 1 |
| Green, NB | 1 |
| Lanier, KS | 1 |
| Bearden, JD | 1 |
| Kugler, JW | 1 |
| Hoff, KL | 1 |
| Reddy, PS | 1 |
| Rowland, KM | 1 |
| Riepl, M | 1 |
| Christensen, B | 1 |
| Romero, TR | 1 |
| Galdino, GS | 1 |
| Silva, GC | 1 |
| Resende, LC | 1 |
| Perez, AC | 1 |
| Côrtes, SF | 1 |
| Duarte, ID | 1 |
| Jørum, E | 1 |
| Warncke, T | 1 |
| Stubhaug, A | 1 |
| Cohen, SP | 1 |
| Chang, AS | 1 |
| Larkin, T | 1 |
| Mao, J | 2 |
| Inomata, S | 1 |
| Kakiuchi, Y | 1 |
| Miyabe, M | 1 |
| Ohara, Y | 1 |
| Sukegawa, I | 1 |
| Osaka, Y | 1 |
| Kohda, Y | 1 |
| Toyooka, H | 1 |
| Lynch, ME | 1 |
| Clark, AJ | 1 |
| Sawynok, J | 1 |
| Sullivan, MJ | 1 |
| Gottrup, H | 1 |
| Bach, FW | 1 |
| Juhl, G | 1 |
| Jensen, TS | 2 |
| Christoph, T | 1 |
| Schiene, K | 1 |
| Englberger, W | 1 |
| Parsons, CG | 1 |
| Chizh, BA | 1 |
| Ben-Ari, A | 1 |
| Lewis, MC | 1 |
| Davidson, E | 1 |
| Richard, BM | 1 |
| Donaldson, MD | 1 |
| Price, DD | 1 |
| Hayes, RL | 1 |
| Lu, J | 1 |
| Mayer, DJ | 1 |
| Frenk, H | 1 |
| Qian, J | 1 |
| Brown, SD | 1 |
| Carlton, SM | 1 |
| Felsby, S | 1 |
| Nielsen, J | 1 |
| Arendt-Nielsen, L | 1 |
| Suzuki, R | 1 |
| Matthews, EA | 1 |
| Dickenson, AH | 1 |
| Rabben, T | 1 |
| Øye, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Assessment of Topical Treatment Response With Amitriptyline and Ketamine: Combination Trial in Chemotherapy Peripheral Neuropathy (ATTRACT-CPN)[NCT00471445] | Phase 3 | 462 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| Auricular Point Acupressure to Manage Chemotherapy Induced Neuropathy[NCT04920097] | 240 participants (Anticipated) | Interventional | 2021-07-08 | Recruiting | |||
| Intravenous Lidocaine Infusion Versus Oral Duloxetine For The Prevention And Treatment Of Chemotherapy Induced Peripheral Neuropathy Among Breast Cancer Patients[NCT04732455] | 60 participants (Actual) | Interventional | 2021-01-15 | Completed | |||
| The Use of Cryotherapy to Prevent Paclitaxel-induced Peripheral Neuropathy and Nail Changes in Women With Breast Cancer[NCT04558034] | 14 participants (Actual) | Interventional | 2020-08-04 | Terminated (stopped due to Principal Investigator retired before study completed.) | |||
| Effect of Cryotherapy in Controlling Peripheral Neuropathy in Cancer Children[NCT04536207] | 60 participants (Anticipated) | Interventional | 2022-02-01 | Recruiting | |||
| Early Detection of Taxane-Induced Neuropathy in Women With Breast Cancer[NCT02549534] | 29 participants (Actual) | Observational | 2015-09-30 | Completed | |||
| Drug Repurposing for the Prevention of Chemotherapy-induced Peripheral Neuropathy (CIPN)[NCT04780854] | Phase 2 | 68 participants (Anticipated) | Interventional | 2020-11-03 | Recruiting | ||
| Effectiveness and Cost-effectiveness of Ozone Therapy in Patients With Pain Secondary to Chemotherapy-induced Peripheral Neuropathy. Randomized, Triple-blind Clinical Trial (O3NPIQ)[NCT04299893] | Phase 2/Phase 3 | 42 participants (Anticipated) | Interventional | 2020-11-30 | Recruiting | ||
| Electro-acupuncture for the Prevention and Treatment of Oxaliplatin-induced Neurotoxicity in Colorectal Cancer Patients: a Prospective, Randomized, Sham-controlled, Double-blinded and Multicenter Study[NCT05798884] | 150 participants (Anticipated) | Interventional | 2023-05-31 | Not yet recruiting | |||
| Diode Laser as a Biomarker for Neuropathic Pain of Peripheral Origin.[NCT06030297] | 301 participants (Anticipated) | Interventional | 2022-11-01 | Recruiting | |||
| Prevalence of Paclitaxel Induced CIPN-Related Pain and CIPN in Indian Patients With Breast Cancer : A Prospective Observational Study[NCT03022162] | 150 participants (Actual) | Observational | 2017-12-01 | Completed | |||
| Prehospital Analgesia With Intra-Nasal Ketamine[NCT02753114] | Phase 4 | 120 participants (Actual) | Interventional | 2017-11-06 | Completed | ||
| Effects of Low-dose Dexmedetomidine-esketamine Combined Nasal Administration at Night on Perioperative Sleep Quality in Breast Cancer Patients: a Randomized, Double-blind, Placebo-controlled Trial[NCT05732064] | Phase 4 | 180 participants (Anticipated) | Interventional | 2023-05-22 | Recruiting | ||
| The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study[NCT00516503] | Phase 3 | 208 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| Antipruritic Effect of Topical Ketamine, Amitriptyline, and Lidocaine[NCT03096444] | Phase 2 | 13 participants (Actual) | Interventional | 2017-05-23 | Terminated (stopped due to Efficacy was not seen after interim analysis) | ||
| Effects of Perioperative Systemic Ketamine on Development of Long-term Neuropathic Pain After Thoracotomy.[NCT00313378] | Phase 3 | 78 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| Study of the Efficiency of the Ketamine With Low Analgesic Doses, in Association With High Opioids, in the Treatment of the Rebels Pains, in Palliative Phase of the Cancerous Disease[NCT01326325] | Phase 3 | 24 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
| Magnesium Oral Supplementation to Reduce Pain in Patients With Severe Peripheral Arterial Occlusive Disease: The MAG-PAPER Randomized Clinical Trial[NCT02455726] | 150 participants (Anticipated) | Interventional | 2015-09-30 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Cancer survivors who completed chemotherapy at least 1 month prior and had Chemotherapy Induced Peripheral Neuropathy (CIPN) (greater than or equal to 4 out of 10) were enrolled. CIPN was assessed using average scores from a 7-day daily diary that asks patients to rate the average pain, numbness, or tingling in their hands and feet over the past 24 hours on an 11-point numeric rating scale at baseline and 6 weeks post intervention. CIPN ranges from 0 (no pain) to 10 (worst possible pain)." (NCT00471445)
Timeframe: Week 6 - Baseline
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Week 6 | |
| Ketamine/Amitriptyline NP-H Cream | 6.55 | 4.93 |
| Placebo Cream | 6.47 | 5.19 |
The scoring algorithm for the parent instrument, the EORTC QLQ-C30, was applied for linearly converting items and subscales of CIPN-20 to 0-100 scales so that a high score corresponds to better condition or less symptom. The secondary analysis was to compare changes from baseline at 4 weeks for the autonomic neuropathy subscale of the CIPN-20. To analyze this endpoint, the area under the curve (AUC) from baseline to week 4 was calculated for each patient's motor neuropathy score. The average AUC for the placebo arm was compared to the average AUC for the topical amitriptyline HCl/ baclofen/ ketamine arm using a Wilcoxon rank sum test. (NCT00516503)
Timeframe: Up to 4 weeks
| Intervention | (units on a scale)*week (Mean) |
|---|---|
| Baclofen-amitriptyline Hydrochloride-ketamine | 85.0 |
| Placebo | 86.8 |
The scoring algorithm for the parent instrument, the EORTC QLQ-C30, was applied for linearly converting items and subscales of CIPN-20 to 0-100 scales so that a high score corresponds to better condition or less symptom. The secondary analysis was to compare changes from baseline at 4 weeks for the motor neuropathy subscale of the CIPN-20. To analyze this endpoint, the area under the curve (AUC) from baseline to week 4 was calculated for each patient's motor neuropathy score. The average AUC for the placebo arm was compared to the average AUC for the topical amitriptyline HCl/ baclofen/ ketamine arm using a Wilcoxon rank sum test. (NCT00516503)
Timeframe: From Baseline to week 4
| Intervention | (units on a scale)* week (Mean) |
|---|---|
| Baclofen-amitriptyline Hydrochloride-ketamine | 69.2 |
| Placebo | 70.1 |
The Peripheral Neuropathy Questionnaire was used to analyze this endpoint. Patient neuropathy symptoms were scored on a 0 - 100 scale (higher score represents less symptomatic). The area under the curve (AUC) from baseline to week 4 was calculated for each patient's score. The average AUC for the placebo arm and the topical amitriptyline HCl/ baclofen/ ketamine arm are reported. (NCT00516503)
Timeframe: Up to 4 weeks
| Intervention | units on a scale * week (Mean) |
|---|---|
| Baclofen-amitriptyline Hydrochloride-ketamine | 172.6 |
| Placebo | 175.7 |
The scoring algorithm for the parent instrument, the EORTC QLQ-C30, was applied for linearly converting items and subscales of CIPN-20 to 0-100 scales so that a high score corresponds to better condition or less symptom. The primary analysis was the change in sensory neuropathy subscale of the CIPN-20 from baseline to week 4. The area under the curve (AUC) from baseline to week 4 was calculated for each patient's sensory neuropathy score. The average AUC for the placebo arm was compared to the average AUC for the topical amitriptyline HCl/ baclofen/ ketamine arm using a Wilcoxon rank sum test. (NCT00516503)
Timeframe: From baseline to 4 weeks
| Intervention | (units on a scale) * week (Mean) |
|---|---|
| Baclofen-amitriptyline Hydrochloride-ketamine | 61.0 |
| Placebo | 60.9 |
Frequency and severity of adverse events reported by patients in weekly diary and evaluated through clinical assessment by NCI CTCAE v3.0. The number of patients reporting grade 3 or higher events are reported in this outcome measure. For a full list of all events, please refer to the Adverse Events section of this report. (NCT00516503)
Timeframe: Up to 4 weeks
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Grade 3+ Adverse Event | Grade 4+ Adverse Event | |
| Baclofen-amitriptyline Hydrochloride-ketamine | 8 | 1 |
| Placebo | 5 | 1 |
Each mood scale (0 - 100, higher is better mood) will be analyzed as an endpoint along with the total mood disturbance score. (NCT00516503)
Timeframe: At 4 weeks
| Intervention | units on a scale (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| POMS Tension-Anxiety Subscale | POMS VA Subscale | POMS Anger-Hostility Score | POMS Confusion-Bewilderment | POMS Depression-Dejection Score | POMS Fatigue-Inertia Score | Mean POMS Score | |
| Baclofen-amitriptyline Hydrochloride-ketamine | 83.2 | 31.1 | 87.8 | 76.9 | 86.4 | 67.2 | 71.5 |
| Placebo | 83.0 | 33.0 | 87.7 | 77.9 | 85.8 | 63.6 | 71.8 |
Pain severity, defined by the four items addressing worst, least, and average pain and pain right now as measured by the BPI will be analyzed identical to the primary endpoint. Additionally, total pain interference as measured by the BPI will be transformed onto a 0-100 ( higher is less pain) point scale. The area under the curve (AUC) from baseline to week 4 was calculated for each patient's score. The average AUC for the placebo arm and the topical amitriptyline HCl/ baclofen/ ketamine arm are reported. (NCT00516503)
Timeframe: Up to 4 weeks
| Intervention | units on a scale * week (Mean) | |||
|---|---|---|---|---|
| Worst Pain | Least Pain | Average Pain | BPI Total Interference | |
| Baclofen-amitriptyline Hydrochloride-ketamine | 58.1 | 78.0 | 66.4 | 76.5 |
| Placebo | 58.7 | 77.3 | 65.4 | 77.3 |
"Peak itch intensity between the vehicle and 4 other active treatments (individual ketamine, amitriptyline, or lidocaine, and KeAmLi-combo). Itch intensity was measured on a 100mm scale visual analog scale for 10 minutes. 0 was weighted with no itch and 100 was weighted with most itch imaginable." (NCT03096444)
Timeframe: 10 minutes
| Intervention | Intensity score (Mean) |
|---|---|
| Topical KeAmLi Combo | 62.7 |
| Topical Ketamine | 63.1 |
| Topical Amitriptyline | 69.2 |
| Topical Lidocaine | 65.8 |
| Topical Vehicle | 61.9 |
Assess mechanical detection and pain thresholds using von Frey filaments stimulators (measured in force mN) to calculate the final threshold as the geometric mean of five series of ascending and descending stimuli. (NCT03096444)
Timeframe: 5 minutes
| Intervention | mN (Mean) | |
|---|---|---|
| Mechanical Detection Threshold | Mechanical Pain Threshold | |
| Topical Amitriptyline | 3.573423965 | 152.4768146 |
| Topical KeAmLi Combo | 3.519376956 | 152.3293608 |
| Topical Ketamine | 3.464204768 | 135.9 |
| Topical Lidocaine | 3.546037659 | 126.9 |
| Topical Vehicle | 3.525692637 | 148.7138273 |
Two standardized quantitative sensory tests are performed to measure warmth detection threshold (assesses the threshold of which warmth sensation is first detected) and heat pain threshold (assesses the threshold at which heat pain sensation is first detected). Measured in change in celsius. (NCT03096444)
Timeframe: 3 minutes
| Intervention | Degrees celsius (Mean) | |
|---|---|---|
| Warm Detection Threshold | Heat Pain Threshold | |
| Topical Amitriptyline | 33.9 | 40.0 |
| Topical KeAmLi Combo | 33.6 | 39.8 |
| Topical Ketamine | 34.0 | 40.0 |
| Topical Lidocaine | 33.7 | 39.4 |
| Topical Vehicle | 33.8 | 39.7 |
3 reviews available for ketamine and Peripheral Nerve Diseases
| Article | Year |
|---|---|
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies.
Topics: Acetylcarnitine; Acetylcysteine; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineoplastic A | 2008 |
Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies.
Topics: Acetylcarnitine; Acetylcysteine; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineoplastic A | 2008 |
Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies.
Topics: Acetylcarnitine; Acetylcysteine; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineoplastic A | 2008 |
Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies.
Topics: Acetylcarnitine; Acetylcysteine; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineoplastic A | 2008 |
Chronic administration of ketamine for analgesia.
Topics: Analgesics; Animals; Chronic Disease; Humans; Ketamine; Neoplasms; Pain, Intractable; Peripheral Ner | 2007 |
9 trials available for ketamine and Peripheral Nerve Diseases
| Article | Year |
|---|---|
A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study of 462 cancer survivors.
Topics: Administration, Topical; Adult; Aged; Amitriptyline; Antineoplastic Agents; Double-Blind Method; Fem | 2014 |
Effects of low-dose intranasal (S)-ketamine in patients with neuropathic pain.
Topics: Administration, Intranasal; Adult; Aged; Algorithms; Anesthetics, Dissociative; Cardiovascular Syste | 2010 |
Effects of low-dose intranasal (S)-ketamine in patients with neuropathic pain.
Topics: Administration, Intranasal; Adult; Aged; Algorithms; Anesthetics, Dissociative; Cardiovascular Syste | 2010 |
Effects of low-dose intranasal (S)-ketamine in patients with neuropathic pain.
Topics: Administration, Intranasal; Adult; Aged; Algorithms; Anesthetics, Dissociative; Cardiovascular Syste | 2010 |
Effects of low-dose intranasal (S)-ketamine in patients with neuropathic pain.
Topics: Administration, Intranasal; Adult; Aged; Algorithms; Anesthetics, Dissociative; Cardiovascular Syste | 2010 |
A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA.
Topics: Administration, Cutaneous; Adrenergic Uptake Inhibitors; Aged; Amitriptyline; Antineoplastic Agents; | 2011 |
Cold allodynia and hyperalgesia in neuropathic pain: the effect of N-methyl-D-aspartate (NMDA) receptor antagonist ketamine--a double-blind, cross-over comparison with alfentanil and placebo.
Topics: Adult; Aged; Alfentanil; Analgesics, Opioid; Cold Temperature; Cross-Over Studies; Double-Blind Meth | 2003 |
The intravenous ketamine test: a predictive response tool for oral dextromethorphan treatment in neuropathic pain.
Topics: Administration, Oral; Adult; Anesthetics, Local; Databases, Factual; Dextromethorphan; Excitatory Am | 2004 |
Topical amitriptyline and ketamine in neuropathic pain syndromes: an open-label study.
Topics: Adenosine; Administration, Topical; Adult; Aged; Aged, 80 and over; Amitriptyline; Analgesics; Analg | 2005 |
Differential effect of ketamine and lidocaine on spontaneous and mechanical evoked pain in patients with nerve injury pain.
Topics: Adult; Aged; Cross-Over Studies; Double-Blind Method; Female; Humans; Ketamine; Lidocaine; Male; Mid | 2006 |
NMDA receptor blockade in chronic neuropathic pain: a comparison of ketamine and magnesium chloride.
Topics: Adult; Aged; Anesthetics, Dissociative; Chronic Disease; Double-Blind Method; Female; Humans; Hypera | 1996 |
NMDA receptor blockade in chronic neuropathic pain: a comparison of ketamine and magnesium chloride.
Topics: Adult; Aged; Anesthetics, Dissociative; Chronic Disease; Double-Blind Method; Female; Humans; Hypera | 1996 |
NMDA receptor blockade in chronic neuropathic pain: a comparison of ketamine and magnesium chloride.
Topics: Adult; Aged; Anesthetics, Dissociative; Chronic Disease; Double-Blind Method; Female; Humans; Hypera | 1996 |
NMDA receptor blockade in chronic neuropathic pain: a comparison of ketamine and magnesium chloride.
Topics: Adult; Aged; Anesthetics, Dissociative; Chronic Disease; Double-Blind Method; Female; Humans; Hypera | 1996 |
NMDA receptor blockade in chronic neuropathic pain: a comparison of ketamine and magnesium chloride.
Topics: Adult; Aged; Anesthetics, Dissociative; Chronic Disease; Double-Blind Method; Female; Humans; Hypera | 1996 |
NMDA receptor blockade in chronic neuropathic pain: a comparison of ketamine and magnesium chloride.
Topics: Adult; Aged; Anesthetics, Dissociative; Chronic Disease; Double-Blind Method; Female; Humans; Hypera | 1996 |
NMDA receptor blockade in chronic neuropathic pain: a comparison of ketamine and magnesium chloride.
Topics: Adult; Aged; Anesthetics, Dissociative; Chronic Disease; Double-Blind Method; Female; Humans; Hypera | 1996 |
NMDA receptor blockade in chronic neuropathic pain: a comparison of ketamine and magnesium chloride.
Topics: Adult; Aged; Anesthetics, Dissociative; Chronic Disease; Double-Blind Method; Female; Humans; Hypera | 1996 |
NMDA receptor blockade in chronic neuropathic pain: a comparison of ketamine and magnesium chloride.
Topics: Adult; Aged; Anesthetics, Dissociative; Chronic Disease; Double-Blind Method; Female; Humans; Hypera | 1996 |
Interindividual differences in the analgesic response to ketamine in chronic orofacial pain.
Topics: Adjuvants, Anesthesia; Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Analgesics | 2001 |
13 other studies available for ketamine and Peripheral Nerve Diseases
| Article | Year |
|---|---|
Can the LANSS scale be used to classify pain in chronic cancer pain trials?
Topics: Aged; Analgesics; Female; Humans; Ketamine; Male; Middle Aged; Neoplasms; Neuralgia; Nociceptive Pai | 2013 |
Interaction between morphine and norketamine enantiomers in rodent models of nociception.
Topics: Analgesics, Opioid; Animals; Constriction, Pathologic; Dose-Response Relationship, Drug; Drug Combin | 2008 |
Effects of norketamine enantiomers in rodent models of persistent pain.
Topics: Animals; Behavior, Animal; Chronic Disease; Constriction, Pathologic; Dose-Response Relationship, Dr | 2008 |
Topical analgesic combinations for bortezomib neuropathy.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Amines; Analgesics; Boronic Acids; Bortezomib; C | 2009 |
Spinally applied ketamine or morphine attenuate peripheral inflammation and hyperalgesia in acute and chronic phases of experimental arthritis.
Topics: Analgesics, Opioid; Anesthetics, Dissociative; Animals; Arthritis, Experimental; Chronic Disease; Fe | 2010 |
Mechanisms and treatment of neuropathic pain.
Topics: Afferent Pathways; Analgesics; Antidepressive Agents; Antidepressive Agents, Tricyclic; Clinical Tri | 2009 |
Ketamine activates the L-arginine/Nitric oxide/cyclic guanosine monophosphate pathway to induce peripheral antinociception in rats.
Topics: Analgesia; Anesthetics, Dissociative; Animals; Arginine; Cyclic AMP; Dinoprostone; Drug Synergism; E | 2011 |
Combined therapy with clonidine and amantadine may act in two stages of glutamate-mediated neuropathic pain caused by a needle puncture in an upper extremity.
Topics: Adrenergic alpha-Agonists; Adult; Amantadine; Analgesics, Non-Narcotic; Calcium Channel Blockers; Ca | 2005 |
The antiallodynic effect of NMDA antagonists in neuropathic pain outlasts the duration of the in vivo NMDA antagonism.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Analgesics, Opioid; Animals; Cold Temperat | 2006 |
Ketamine and muscle spasm.
Topics: Child; Humans; Ketamine; Male; Muscle Contraction; Paralysis; Peripheral Nervous System Diseases; Ra | 1994 |
Intrathecal treatment with dextrorphan or ketamine potently reduces pain-related behaviors in a rat model of peripheral mononeuropathy.
Topics: Animals; Behavior, Animal; Dextrorphan; Injections, Spinal; Ketamine; Male; Pain; Pain Measurement; | 1993 |
Systemic ketamine attenuates nociceptive behaviors in a rat model of peripheral neuropathy.
Topics: Animals; Behavior, Animal; Cold Temperature; Dose-Response Relationship, Drug; Excitatory Amino Acid | 1996 |
Comparison of the effects of MK-801, ketamine and memantine on responses of spinal dorsal horn neurones in a rat model of mononeuropathy.
Topics: Animals; Dizocilpine Maleate; Electric Stimulation; Electrophysiology; Excitatory Amino Acid Antagon | 2001 |